Answers are grounded in this paper and cite their sources.
Purposeof the research: Diabetic peripheral neuropathy induces progressive gait deterioration, yet most Machine Learning (ML)-based gait studies rely on binary classification frameworks that fail to capture the stage-wise biomechanical changes occurring across the diabetes neuropathy continuum. To identify stage-consistent and stage-specific gait biomarkers across three clinical groups healthy controls (N), diabetes without neuropathy (D), and diabetes with peripheral neuropathy (DPN) using an interpretable machine learning framework.MethodsGait data were collected from 394 participants (N = 109, D = 163, DPN = 122) using the Zebris FDM platform. Spatiotemporal, plantar pressure, and symmetry parameters were extracted. Four pairwise classification tasks (N vs D, D vs DPN, N vs DPN, Healthy vs Diseased) were evaluated using Results: Support Vector Machine (SVM), Random Forest, Extreme Gradient Boosting (XGBoost), and Logistic Regression under stratified five-fold cross-validation. Cross-validated SHapley Additive exPlanations (SHAP)-based feature selection and a final XGBoost model were used for biomarker identification and interpretation. SVM achieved the highest area under the receiver operating characteristic curve (AUC) across all tasks (N vs D: 0.80, D vs DPN: 0.75, N vs DPN: 0.91, Healthy vs Diseased: 0.85). SHAP analysis identified bilateral heel contact time and step length as stage-consistent core biomarkers, present across all four classification tasks. Stage-specific discriminators included forefoot load-timing disruption in early diabetes, midfoot unloading and lateral symmetry reversal at the neuropathic transition, and posterior Centre of Pressure (CoP) displacement in established neuropathy.ConclusionsDiabetic gait pathology progresses in a measurable, stage-ordered sequence from early forefoot load-timing disruption through midfoot redistribution and symmetry reversal at the neuropathic transition, to global spatiotemporal deterioration in established neuropathy. The stage-wise biomarker framework presented here provides an interpretable, clinically grounded basis for gait-based screening of diabetic neuropathic progression, warranting prospective validation.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: